Remimazolam With Planned Flumazenil Reversal Versus Sevoflurane-based Balanced Anesthesia for Hysteroscopic Day Surgery: A Randomized Controlled Trial

This prospective, single-center, randomized controlled trial aims to compare remimazolam anesthesia with planned flumazenil reversal and sevoflurane-based balanced anesthesia in adult women undergoing ambulatory hysteroscopic surgery.
Participants will be randomly assigned in a 1:1 ratio to receive either remimazolam for induction and maintenance followed by flumazenil reversal or propofol induction followed by sevoflurane-based balanced anesthesia. The primary outcome is anesthesia-controlled time, defined as the sum of induction time and emergence time. Secondary outcomes include recovery profiles, postoperative symptoms, quality of recovery, hemodynamic stability, and the incidence of re-sedation. The study will evaluate whether a remimazolam-flumazenil strategy can improve operating room efficiency while maintaining recovery quality and safety comparable to conventional sevoflurane-based anesthesia in the ambulatory surgery setting.

Start Date01 Jun 2026

Sponsor / Collaborator-

CTIS2025-523543-36-00

/ RecruitingPhase 4IIT

Study on the influence of FLUMAzenil regarding the incidence of pediatric emergence delirium (ED) in children undergoing ENT surgery – FLUMA Study

Start Date18 May 2026

Sponsor / Collaborator-

ChiCTR2600122589

/ SuspendedPhase 4

**Effects of Ciprofol, Remimazolam, and Remimazolam-Flumazenil on the Recovery Efficiency of General Anesthesia in Gynecological Ambulatory Surgery: A Prospective Randomized Controlled Study**

Start Date01 Apr 2026

Sponsor / Collaborator

Weifang Peoples Hospital

100 Clinical Results associated with Flumazenil

100 Translational Medicine associated with Flumazenil

100 Patents (Medical) associated with Flumazenil

4,519

Literatures (Medical) associated with Flumazenil

03 Oct 2026·CLINICAL TOXICOLOGY

Flumazenil use in acute poisoning: improved composite clinical outcomes in a propensity-matched retrospective cohort study

Article

Author: Choi, Sze Yi ; Liu, Shan

INTRODUCTION:

Despite being an effective benzodiazepine antagonist, flumazenil is not routinely used in patients with overdose due to the potential risk of major adverse events. Although recent studies have reported a low rate of major adverse events, the benefit of its utility on clinical outcomes remains unclear. This study aims to determine the effect of flumazenil treatment on the clinical outcomes of comatose patients with acute benzodiazepine or nonbenzodiazepine hypnotics poisoning.

METHODS:

This was a retrospective observational study on consecutive adult patients reported to the Hong Kong Poison Control Centre from 1 July 2008 to 31 December 2024 for benzodiazepine or nonbenzodiazepine hypnotics overdose with Glasgow Coma Scale eight or less. Patients treated with flumazenil, the intervention, were matched with patients in the control group by propensity score matching. The Finkelstein-Schoenfeld method with matched pairs approach was used to compare the primary outcome, a hierarchical composite endpoint consisting of in-hospital death, intensive care unit admission, and length of hospital stay. Secondary outcomes included mechanical ventilation and pneumonia within two days.

RESULTS:

A total of 599 patients were included for propensity score matching, and 98 patients in the intervention group and 501 patients in the control group were matched in a 1:1 ratio. Two patients in the intervention group and one patient in the control group died during the in-patient episode of care; the deaths in the intervention group were not attributed to flumazenil. The hierarchical composite endpoint (in-hospital death, then ICU admission, then length of hospital stay) in the interventional group was significantly improved, with a win ratio of 1.68 (95% CI 1.17-2.41). The ICU admission rate (42.9% vs 69.4%, P <0.001) and the proportion of patients who received mechanical ventilation (35.7% versus 65.3%, P <0.001) was significantly lower in the intervention group. No difference was found in the death, length of stay and occurrence of rapid-onset pneumonia.

DISCUSSION:

These results indicate the improvement of primary outcome in the intervention group was predominantly attributed to the reduction in ICU admission and mechanical ventilation. The effect size of flumazenil treatment could be partially offset by the adoption of non-invasive airway management strategy.

CONCLUSION:

Among comatose patients with acute benzodiazepine or nonbenzodiazepine hypnotics poisoning, flumazenil treatment was associated with reduction in ICU admission and mechanical ventilation; as well as a better outcome for the composite endpoint of in-hospital death, ICU admission rate, and length of hospital stay.

01 Oct 2026·JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Comparison of recovery profiles after anesthesia with remimazolam and flumazenil versus propofol for short-duration gynecological surgery: A prospective, randomized, single-blind trial

Article

Author: Park, Young Ha ; Park, Youngsoo ; Choi, Eunsu ; Lee, Yoon Sook ; Kim, Sunwoo

Objective:

This study aimed to compare the recovery profiles after anesthesia with remimazolam reversed by flumazenil versus propofol among patients undergoing short-duration gynecological surgeries.

Methods:

In this prospective, single-blind, randomized trial, 86 patients were assigned to either the propofol group (n = 43, received propofol and remifentanil) or the remimazolam group (n = 43, received remimazolam and remifentanil). At the end of the surgery, patients in the propofol group received 2 mg/kg sugammadex, whereas those in the remimazolam group received 2 mg/kg sugammadex combined with 200 μg flumazenil. Recovery was measured across immediate, intermediate, and long-term phases.

Results:

Eye-opening and extubation times were significantly shorter in the remimazolam group ( p < .001). However, the the postanesthetic care unit stay times were significantly longer in this group due to institutional safety protocols ( p < .001). No statistical differences were found in the Quality of Recovery-15 K scores or other long-term recovery profiles at 4 h or 1 day postoperatively.

Conclusions:

Remimazolam–flumazenil significantly improved immediate recovery; however, its effects on the broader recovery trajectory were not significantly different from those of propofol, the most commonly used drug. Although Quality of Recovery-15 K scores were numerically higher in the remimazolam group, the difference was not statistically significant.Trial registration: Clinical Research Information Service (CRIS), KCT0008314.

01 Sep 2026·JOURNAL OF PSYCHIATRIC RESEARCH

Comparative diagnostic accuracy of panic provocation tests: A meta-analysis

Review

Author: Iosifescu, Dan V ; Tural, Umit ; Shannon, Sara Rose

Panic provocation tests have been widely used to investigate the biological underpinnings of panic disorder (PD). However, their diagnostic specificity remains uncertain, as several agents can also induce panic-like reactions in healthy individuals. This meta-analysis estimated and compared diagnostic odds ratios (DORs) across different provocation methods. Random-effects meta-analyses were conducted using the Hartung-Knapp adjustment. Based on 123 studies including 5693 participants, sodium lactate infusion showed the highest pooled DOR (24.77, 95% CI 19.03-32.25, GRADE certainty = High), followed by isoproterenol (18.85, 95% CI 12.39-28.66, GRADE certainty = Moderate), cholecystokinin tetrapeptide (CCK-4; 15.03, 95% CI 7.83-28.84, GRADE certainty = Moderate), meta-chlorophenyl piperazine (m-CPP; 14.51, 95% CI 4.67-45.07, GRADE certainty = Low), caffeine (14.11, 95% CI 4.79-41.54, GRADE certainty = Moderate), hyperventilation (11.89, 95% CI 6.51-21.73, GRADE certainty = High), carbon dioxide inhalation (CO₂; 11.12, 95% CI 8.63-14.32, GRADE certainty = High), and yohimbine (7.87, 95% CI 1.12-55.13, GRADE certainty = Very low). Breath holding, fenfluramine and flumazenil did not demonstrate statistically significant discriminative ability. Meta-regression analysis confirmed that sodium lactate yielded significantly higher DORs than m-CPP, hyperventilation, CO₂, fenfluramine, flumazenil, and yohimbine. No substantial between-study heterogeneity or publication bias was identified across the pooled analyses. These findings suggest that provocation methods targeting acid-base balance, especially sodium lactate infusion, are associated with superior diagnostic discrimination between individuals with PD and healthy controls.

News (Medical) associated with Flumazenil

08 Jul 2026

·www.hikma.com

Hikma launches Diazepam Injection, USP in the US

Hikma launches Diazepam Injection, USP in the US London, UK, 8 July 2026 – Hikma Pharmaceuticals PLC (Hikma, Group), a multinational pharmaceutical company, today announced the launch of Diazepam Injection, USP, C-IV, 5 mg/mL (10 mg/2 mL), in 2 mL multi-dose vials, supplied in packs of 25, in the US. “We are pleased to expand our injectable portfolio with the launch of Diazepam Injection, USP 10mg/2 mL multi-dose vial in the US following the launch of Diazepam Injection USP 50 mg/10 mL multidose vial in 2023,” said Jon Kafer, Vice President of Commercial for US Injectables. “This addition reflects our commitment to providing clinicians and patients with a comprehensive range of dosage options, ensuring reliable and convenient access to high-quality, affordable medicines across a range of care settings.” Diazepam Injection, USP is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety; as an adjunct in the symptomatic relief of acute agitation, tremor, and delirium tremens in acute alcohol withdrawal; as an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present; as an adjunct for the relief of skeletal muscle spasm; as a useful adjunct in status epilepticus; and as a premedication for relief of anxiety and tension in patients undergoing surgical procedures or cardioversion. Please see the full package insert for boxed warning and other important safety information. According to IQVIA, the total US market for Diazepam Injection was approximately $77 million and 4.1 million units for the full year 2025. - ENDS – This product has been approved for marketing in the United States by the US FDA. This product approval does not confer the right on Hikma, or any other party, to market this product outside the United States. About Hikma Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch) Download full press release Enquiries Hikma Pharmaceuticals PLC Susan Ringdal EVP, Strategic Planning and Global Affairs +44 (0)20 7399 2760/ +44 7776 477050 Steven Weiss US Communications +1 732 788 8279 Important Safety Information for Diazepam Injection, USP, C-IV WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS CONTRAINDICATIONS Diazepam is contraindicated in patients with a known hypersensitivity to this drug; acute narrow angle glaucoma; and open angle glaucoma unless patients are receiving appropriate therapy. WARNINGS & PRECAUTIONS ADVERSE REACTIONS Side effects most commonly reported were drowsiness, fatigue and ataxia; venous thrombosis and phlebitis at the site of injection. Other adverse reactions less frequently reported include: CNS: confusion, depression [including respiratory depression], dysarthria, headache, hypoactivity, slurred speech, syncope, tremor, vertigo. G.I.: constipation, nausea. G.U.: incontinence, changes in libido, urinary retention. Cardiovascular: bradycardia, cardiovascular collapse, hypotension. EENT: blurred vision, diplopia, nystagmus. Skin: urticaria, skin rash. Other: hiccups, changes in salivation, neutropenia, jaundice. Paradoxical reactions such as acute hyperexcited states, anxiety, hallucinations, increased muscle spasticity, insomnia, rage, sleep disturbances and stimulation have been reported; should these occur, use of the drug should be discontinued. Minor changes in EEG patterns, usually low-voltage fast activity, have been observed in patients during and after diazepam therapy and are of no known significance. In peroral endoscopic procedures, coughing, depressed respiration, dyspnea, hyperventilation, laryngospasm and pain in throat or chest have been reported. Because of isolated reports of neutropenia and jaundice, periodic blood counts and liver function tests are advisable during long-term therapy. DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mμ receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If diazepam is to be combined with other psychotropic agents or anticonvulsant drugs, careful consideration should be given to the pharmacology of the agents to be employed - particularly with known compounds which may potentiate the action of diazepam, such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants. In highly anxious patients with evidence of accompanying depression, particularly those who may have suicidal tendencies, protective measures may be necessary. Diazepam injection has produced hypotension or muscular weakness in some patients particularly when used with narcotics, barbiturates or alcohol. The clearance of diazepam and certain other benzodiazepines can be delayed in association with cimetidine administration. The clinical significance of this is unclear. USE IN SPECIFIC POPULATIONS Pediatric Use Efficacy and safety of parenteral diazepam has not been established in the neonate (30 days or less of age). Prolonged central nervous system depression has been observed in neonates, apparently due to inability to biotransform diazepam into inactive metabolites. Benzyl alcohol has been reported to be associated with a fatal gasping syndrome in premature infants. Pregnancy Advise pregnant females that use of diazepam late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate. Benzodiazepines cross the placenta and may produce respiratory depression, hypotonia, and sedation. Monitor neonates exposed to Diazepam injection during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor neonates exposed to Diazepam injection during pregnancy for signs of withdrawal; manage these neonates accordingly. Instruct patients to inform their healthcare provider if they are pregnant. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to diazepam during pregnancy. Nursing Advise patients that breastfeeding is not recommended during treatment with diazepam. Diazepam is present in breastmilk. There are reports of sedation, poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk. However, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Diazepam injection and any potential adverse effects on the breastfed infant from Diazepam injection or from the underlying maternal condition. OVERDOSAGE Overdosage is characterized by CNS depression ranging from drowsiness to coma. Manage with general supportive measures including intravenous fluids and airway maintenance. Flumazenil may be used adjunctively to, not a substitute for, supportive management of benzodiazepine overdose. Flumazenil can lead to withdrawal and adverse reactions, including seizures, particularly in the context of mixed overdosage with drugs that increase seizure risk (e.g., tricyclic and tetracyclic antidepressants) and in patients with long term benzodiazepine use and physical dependency. The risk of withdrawal seizures with flumazenil use may be increased in patients with epilepsy. Flumazenil is contraindicated in patients given benzodiazepines for control of a potentially life-threatening condition (e.g., status epilepticus). See the flumazenil injection Prescribing Information. Consider contacting a poison center (1-800-222-1222), poisoncontrol.org or a medical toxicologist for additional overdosage management recommendations. INDICATIONS AND USAGE Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient’s recall of the procedures. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus. Diazepam injection is a useful adjunct in status epilepticus. Diazepam is a useful premedication (the intramuscular route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient’s recall of the procedure. ENDING INFORMATION For additional information, please refer to the Package Insert for full prescribing information, available on www.hikma.com. To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Manufactured by: Hikma Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922 USA © 2026. Hikma Pharmaceuticals USA Inc. All rights reserved. HK-3574-v1

Drug Approval

31 Mar 2026

·www.fiercepharma.com

API supplier BASF raises prices up to 20% in response to rising energy, raw material costs

The war in the Middle East has prompted supply concerns across industries and caused global oil prices to rise sharply. With conflict in the Middle East bringing on a global energy market squeeze, one major pharma supplier is raising prices across its excipients and active pharmaceutical ingredient (API) portfolio.Global chemical production company BASF Pharma Solutions is increasing its prices by up to 20% for its excipients and a select array of its APIs, the company announced in a Monday press release. The price change will take effect immediately or as BASF’s existing contracts allow. “The adjustment supports BASF’s commitment to maintaining a reliable supply of high-quality products across its portfolio amid rising global energy and raw material costs,” the company said. BASF will continue to monitor market conditions and may make future adjustments as needed, it noted. Excipients are inactive ingredients that play a crucial role in drug formulations along with APIs. A month into the U.S. and Israel’s war with Iran, rising energy costs have touched many industries. Much of the supply concerns revolve around the effective closure of the Strait of Hormuz, a key passageway that is responsible for the flow of about 20% of the world’s crude oil and natural gas. Oil prices have risen sharply since the initial attack on Iran in late February.Rising oil prices could affect the supply chain of “most global manufacturers,” Aaron Lober, manufacturing intelligence lead at AI production platform developer CADDi, told Fierce Pharma in a statement earlier this month. While “very few” manufactured goods pass through the Strait of Hormuz, Lober said, the bigger issue becomes “how rising oil prices ripple through transportation and energy costs across the entire system.” Several large global pharmas have said that they are keeping an eye on their employees and medicine supply amid the evolving conflict. Executives at some Western drugmakers, speaking anonymously, previously told Reuters that they are looking at alternative routes into the Gulf and trucking some drugs over land rather than using sea lanes.While the Middle East is only responsible for 0.3% of the world’s API production, a few select drugs stand to be particularly affected, according to a recent report from The Hill. For example, Jordan produces about half of the global supply of amoxicillin oral suspension and about half of the world’s API for fast-acting anesthetic etomidate. Further, 73% of API for benzodiazepine antagonist flumazenil is made between Jordan and Israel, according to the report.If the situation continues, Gerren McHam, VP of external affairs at the API Innovation Center, warned The Hill that supply chain lead times, transportation costs and key starting materials could be affected. In England, the head of the National Health Service (NHS), Sir Jim Mackey, is “really worried” about medical supplies and shortages, telling LBC radio show host Nick Ferrari that “everything’s at risk.”The U.S., however, shouldn’t see shortages for generic medicines for at least a few more weeks, given available buffer stocks, Rohit Tripathi, vice president of industry strategy for manufacturing at RELEX Solutions, told CNBC on March 16. Nearly half of generic prescriptions sold in the U.S. come from India, which in turn depends on the Strait of Hormuz for about 40% of its crude oil imports.

26 Mar 2026

·endpoints.news

UCB picks Georgia for $2B biologics site; AbbVie exec visits China

UCB has selected Gwinnett County, GA, as the location for its new biologics factory. The 460,000-square-foot facility is expected to cost $2 billion and will supply biologics to the US market, a spokesperson told Endpoints News. The site will create 330 new jobs. China is on the forefront of pharma companies’ minds, and AbbVie is no exception. The company’s senior vice president Jerome Bouyer visited China this week, noting that AbbVie is “actively” looking to partner with local clinical research centers and “innovative” companies. The US is at risk of potential prescription and hospital drug shortages due to the ongoing Iran war, according to a report from the drug supply and quality nonprofit US Pharmacopeia . Nearly half of the US’ amoxicillin oral suspension, prescribed to treat bacterial infections, and the active pharmaceutical ingredients for the anesthetic drug etomidate are made in Jordan, the report shows. Meanwhile, 73% of API for the drug flumazenil, used to reverse anesthesia-induced sedation, comes from Israel and Jordan. In other manufacturing news:

100 Deals associated with Flumazenil

External Link

KEGG	Wiki	ATC	Drug Bank
D00697	Flumazenil	V03AB25	DB01205

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hyperemesis Gravidarum	China	Zhejiang Qo Tuo Kang Pharmaceutic	01 Jan 1998
Sedation	Japan	Sandoz KK	21 Jan 1992
Consciousness	United States	Hoffmann-La Roche, Inc.	20 Dec 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sleep Initiation and Maintenance Disorders	Phase 1	Israel	Coeruleus Ltd.	01 Jul 2010
Drug abuse	Preclinical	United States	Bexson Biomedical, Inc.	18 Jul 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05397886 (Pubmed)	Not Applicable	Atrial Fibrillation	53	Remimazolam-flumazenil	brusaqlsit(lqvtmoyduz) = nqntulkwmc orgzgesigi (cvnjyahqds, 157 - 216)	Positive	03 Jun 2024
				Propofol	brusaqlsit(lqvtmoyduz) = nkgpypkzgo orgzgesigi (cvnjyahqds, 230 - 483)
NCT05435911 (Pubmed \| Eur J Anaesthesiol) Manual	Not Applicable	Anesthesia	-	Propofol	dqbffyqnhb(jxfywwatea) = tbhfxpcvsc cyjgyasrbh (hpvrnrtdmm, 140) View more	Positive	12 Jan 2024
				Remimazolam/flumazenil	dqbffyqnhb(jxfywwatea) = wnhtksbcqk cyjgyasrbh (hpvrnrtdmm, 51) View more
NCT03440112 (GABA-A, CTgov)	Phase 1/2	Ataxia \| Parkinson Disease	34	Flumazenil (Transdermal Flumazenil (Active))	klzdheukqd(uywqewrmnk) = rxypuoyvnv zkjhyprgfe (ptnlzmbuhk, qapttgloeo - uccauuhhgh) View more	-	10 Jan 2023
				Placebo (Placebo Cream)	klzdheukqd(uywqewrmnk) = byygemcyub zkjhyprgfe (ptnlzmbuhk, kstvacfuay - gemrpnppju) View more
NCT03462641 (CTgov)	Phase 1/2	Ataxia \| Parkinson Disease	36	placebo (Placebo)	temhoodues(rivqdrjnsu) = uagrfatfkh uylcvmrmbj (hfljzhwgxz, 2.36) View more	-	29 Jun 2022
				Flumazenil (Flumazenil)	temhoodues(rivqdrjnsu) = bqhrrxztim uylcvmrmbj (hfljzhwgxz, 2.34) View more
NCT03959189 (CTgov)	Phase 1	Myotonic Dystrophy	12	ERX-963 (Cohort 1: 1 mg ERX-963)	aihkjbwpvr = xwlnqlpihl uctsjdtkzx (gjifmjgjwl, cmxgakzmwe - ectcwgafom) View more	-	23 Jun 2021
				ERX-963 (Cohort 2: 2 mg ERX-963)	aihkjbwpvr = mwalojekzr uctsjdtkzx (gjifmjgjwl, jppwpjwxbk - viosocfglr) View more
NCT02899156 (FLYP, CTgov)	Phase 4	Delirium	22	Flumazenil (Flumazenil Group)	xokzcgukxp(xawnvhsblk) = hrwvdjqfbr sazzqdubvr (uqtuukxyoq, pxcsaxiokh - pxaimedhoc) View more	-	23 Jul 2020
				Placebo (Placebo Group)	xokzcgukxp(xawnvhsblk) = usqsaozhgo sazzqdubvr (uqtuukxyoq, ahntnefjpq - cnlwyirmtm) View more
UEGW2017	Not Applicable	Pneumonia, Aspiration	-	Flumazenil	focjiieaml(hequnkfplk) = dlgefsduwp qplpfdeaun (ykijfpwqnx )	-	01 Oct 2017
				No Flumazenil	focjiieaml(hequnkfplk) = tccwmvrhjg qplpfdeaun (ykijfpwqnx )
NCT01183312 (CTgov)	Phase 1/2	Narcolepsy \| Idiopathic Hypersomnia \| Primary Hypersomnia ... View more	10	placebo (Placebo)	zecyneopff(luhtcyephw) = mawyflpzmd dozviryzul (uzmmpzmngm, 28.2) View more	-	27 Mar 2013
				Flumazenil (Sublingual Flumazenil)	zecyneopff(luhtcyephw) = unhebwvgzg dozviryzul (uzmmpzmngm, 63.7) View more
NCT00262639 (CTgov)	Phase 2/3	Alcoholism \| Alcohol Withdrawal Delirium	60	Flumazenil+Gabapentin (Low CIWA Flumazenil/Gabapentin)	mpxtnyybno = ztigvkfoiu fuqditnmzx (wkxvmmvozh, tofqxhrpqx - fxmopdysms) View more	-	14 Aug 2009
				Placebo (Low CIWAar Placebo)	mpxtnyybno = wvzkothakc fuqditnmzx (wkxvmmvozh, xfqdcusrng - byfuwrrstb) View more
Pubmed \| Can Anaesth Soc J	Phase 4	-	40	Flumazenil 1 mg	xcknmdnfvm(slnysffvmg) = Flumazenil improves the overall quality of emergence, including patients' subjective feeling meinzbpbyh (mkglyivyri )	-	01 Nov 2001
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis